casein-kinase-ii and Cystadenocarcinoma--Serous

Ten-eleven translocation methylcytosine dioxygenase-1, TET1, takes part in active DNA demethylation. However, our understanding of DNA demethylation in cancer biology and its clinical significance remain limited. This study showed that TET1 expression correlated with poor survival in advanced-stage epithelial ovarian carcinoma (EOC), and with cell migration, anchorage-independent growth, cancer stemness, and tumorigenicity. In particular, TET1 was highly expressed in serous tubal intraepithelial carcinoma (STIC), a currently accepted type II EOC precursor, and inversely correlated with TP53 mutations. Moreover, TET1 could demethylate the epigenome and activate multiple oncogenic pathways, including an immunomodulation network having casein kinase II subunit alpha (CK2α) as a hub. Patients with TET1

Topics: Animals; Carcinoma, Ovarian Epithelial; Casein Kinase II; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cystadenocarcinoma, Serous; Epithelial-Mesenchymal Transition; Fallopian Tube Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Mixed Function Oxygenases; Ovarian Neoplasms; Prognosis; Proto-Oncogene Proteins